Among patients who took at least two doses of medication, GLP-1 receptor agonists were associated with a significantly lower ...

During the years when patients got the same anesthetic management regardless of whether they were on a GLP-1 receptor agonist ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 ...

While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...

There are several types of GLP-1 medications available, each with varying dosing schedules and forms of administration. Some ...

GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...

Semaglutide and tirzepatide helped Texas woman Kathryn Dean lose 18kg and keep the weight off, and she is no longer diagnosed ...

Prescribing for both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in a type 1 diabetes (T1D) population identified in a database increased ...

The retrospective study points to fewer suicidal thoughts or attempts among adolescents taking semaglutide or liraglutide.

Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.

While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs ...

An analysis of over 400,000 patients with T1D revealed a rise in prescribing for glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors over the past decade.